Aug 11, 2026 04:02PM
Jul 27, 2026 08:00AM
Jul 27, 2026 08:00AM
Jun 22, 2026 08:02AM
Jun 22, 2026 08:00AM
Jun 3, 2026 08:03AM
Jun 3, 2026 08:00AM Kyverna Therapeutics Highlights Updated Miv-cel Data at EULAR Demonstrating Substantial Reduction in Disease Activity in ACPA-Positive, Treatment Refractory Rheumatoid Arthritis
May 12, 2026 04:02PM
May 12, 2026 04:02PM
May 4, 2026 08:00AM
May 4, 2026 08:00AM
Apr 22, 2026 09:38AM
Apr 22, 2026 07:03AM
Apr 21, 2026 06:45PM Kyverna Presents Registrational Trial Primary Analysis for Miv-cel in Stiff Person Syndrome Demonstrating Statistically Significant, Durable Clinical Benefit Across All Endpoints in an Oral, Late-Brea
Apr 20, 2026 08:02AM
Apr 20, 2026 08:00AM
Apr 9, 2026 08:00AM
Mar 26, 2026 04:02PM
Mar 5, 2026 04:21PM
Mar 5, 2026 04:21PM
Jan 12, 2026 08:09AM Kyverna appoints Christi Shaw as executive chairperson, plans 2026 BLA filing
Jan 12, 2026 08:00AM
Dec 15, 2025 06:30AM
Dec 15, 2025 06:30AM
Nov 12, 2025 04:05PM
Oct 29, 2025 06:30AM
Oct 29, 2025 06:30AM
Sep 15, 2025 01:02PM Kyverna to present Phase 2 myasthenia gravis data at AANEM meeting
Sep 15, 2025 01:02PM
Aug 28, 2025 08:00AM
Aug 28, 2025 08:00AM
Aug 28, 2025 08:00AM
Aug 28, 2025 08:00AM
Aug 20, 2025 05:06AM
Aug 12, 2025 04:02PM Kyverna Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results
Jul 29, 2025 08:30AM
May 13, 2025 04:02PM
Apr 3, 2025 06:46AM
Mar 31, 2025 08:59AM
Mar 27, 2025 04:02PM
Mar 24, 2025 09:13AM
Mar 17, 2025 03:01PM Notice to Long-Term Shareholders of Fluence Energy, Inc. (NASDAQ: FLNC); Kyverna Therapuetics, Inc. (NASDAQ: KYTX); Mercury Systems, Inc. (NASDAQ: MRCY); and Sage Therapeutics, Inc. (NASDAQ: SAGE): Gr
Mar 13, 2025 06:21PM
Jan 13, 2025 07:30AM
Nov 13, 2024 04:14PM
Aug 15, 2024 06:41AM
Aug 12, 2024 04:08PM
Aug 12, 2024 04:05PM
Aug 12, 2024 04:05PM Kyverna Therapeutics Receives U.S. FDA RMAT Designation for KYV-101 in the Treatment of Patients With Progressive Myasthenia Gravis
Jul 16, 2024 10:54AM

328,147 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All